Unternehmensprofil · Healthcare

Becton Dickinson and Company

BDX · USA
Börse
USA
Land / Region
USA
Börsengang
1. Januar 1987
Mitarbeiter
60.000
Website
www.bd.com
Aktueller Kurs
$143.98
Live · 18. Juni 2026
Baillie-Wachstumsscore
40/100
Eher schwach
Innerer Wert · Drei-Stufen-Bereich Aktueller Kurs $143.98 Live · Zwischen dem konservativen und dem fairen Bereich

Zusammengesetzter Bewertungsbereich · konservativ $108–$125 / fair $154–$178 / optimistisch $217–$249. Bei $143.98, Zwischen dem konservativen und dem fairen Bereich.

Bei Veröffentlichung $147.63 (24. Mai 2026)

Noch keine Analysen zu dieser Aktie in Ihrer Sprache.

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care

Marktkapitalisierung39,02 Mrd. $
Umsatz (TTM)22,23 Mrd. $
EBITDA6,16 Mrd. $
Nettomarge5,12 %
ROE6,67 %
KGV (TTM)24,71
Erwartetes KGV10,49
PEG1,11
EPS5,73 $
Dividendenrendite2,88 %
52-Wochen-Spanne125,21 $ – 184,86 $
Analysten-Kursziel180,69 $
Analystenbewertung3.8 / 5

Daten von EODHD, dargestellt in der Berichtswährung; nur zu Informationszwecken, keine Anlageberatung.

Geschichte

DemnächstDieser Abschnitt wird gerade ergänzt — schauen Sie bald wieder vorbei.

Branchenposition

DemnächstDieser Abschnitt wird gerade ergänzt — schauen Sie bald wieder vorbei.